Na+/H+ exchanger regulatory factor 1 overexpression suppresses the malignant phenotype of MIAPaCa-2 pancreatic adenocarcinoma cells by downregulating Akt phosphorylation

Na+/H+ exchanger regulatory factor 1 (NHERF1) is reported to be associated with the development of numerous types of tumor; however, its effects on the metastasis of pancreatic adenocarcinoma are not fully understood. In the present study, it was revealed that the expression level of NHERF1 in pancreatic adenocarcinoma is decreased compared with normal pancreatic tissue based on the analysis of a protein expression database. The present study was undertaken in order to investigate the potential effects of NHERF1 overexpression on the malignant phenotype of MIAPaCa-2 pancreatic adenocarcinoma cells. NHERF1 was stably overexpressed in this cell line, and Cell Counting Kit-8, wound healing and Transwell assays were used to detect the proliferative and migratory abilities of the cells. NHERF1 overexpression suppressed proliferation in the MIAPaCa-2 cell line compared with empty vector-transfected (negative control) cells. Additionally, NHERF1 overexpression significantly inhibited the migration of MIAPaCa-2 cells. The results of a western blot analysis identified that NHERF1 overexpression markedly decreased the expression of phosphorylated-protein kinase B (p-Akt), while no significant difference was observed between untransfected and negative control cells. Taken together, these results suggested that NHERF1 may be able to inhibit the proliferation and migration and alter the malignant phenotype of pancreatic adenocarcinoma cells via reduction of p-Akt levels. These findings indicate a potential novel approach to the treatment of pancreatic adenocarcinoma.

[1]  Xueran Chen,et al.  A novel splice variant of supervillin, SV5, promotes carcinoma cell proliferation and cell migration. , 2017, Biochemical and biophysical research communications.

[2]  N. Copeland,et al.  KRAS-related proteins in pancreatic cancer. , 2016, Pharmacology & therapeutics.

[3]  Stephen L. Abrams,et al.  Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. , 2016, Biochimica et biophysica acta.

[4]  G. Lesinski,et al.  Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities , 2016, Molecular Cancer Therapeutics.

[5]  D. Goldstein,et al.  Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. , 2016, Anticancer research.

[6]  Soon-Sun Hong,et al.  HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer , 2016, Oncotarget.

[7]  Yue Zhang,et al.  EBP50 interacts with EGFR and regulates EGFR signaling to affect the prognosis of cervical cancer patients. , 2016, International journal of oncology.

[8]  E. Miyoshi,et al.  Application of glycoscience to the early detection of pancreatic cancer , 2016, Cancer science.

[9]  Yuan-yuan Zhu,et al.  MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway , 2016, OncoTargets and therapy.

[10]  Namrata Vijayvergia,et al.  Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? , 2016, Journal of gastrointestinal oncology.

[11]  M. Georgescu,et al.  NHERF1/EBP50 Suppresses Wnt-β-Catenin Pathway–Driven Intestinal Neoplasia1 , 2016, Neoplasia.

[12]  Yan Wang,et al.  NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer , 2016, Oncotarget.

[13]  Q. Ma,et al.  Targeting of NHERF1 through RNA interference inhibits the proliferation and migration of metastatic prostate cancer cells. , 2016, Oncology letters.

[14]  A. Paradiso,et al.  The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells. , 2015, International journal of oncology.

[15]  Hongli Li,et al.  EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway , 2014, Medical Oncology.

[16]  Q. Ma,et al.  Breast cancer‐derived K172N, D301V mutations abolish Na+/H+ exchanger regulatory factor 1 inhibition of platelet‐derived growth factor receptor signaling , 2013, FEBS letters.

[17]  Y. Li,et al.  EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation , 2012, Amino Acids.

[18]  D. Lallemand,et al.  Contact-dependent inhibition of EGFR signaling by Nf2/Merlin , 2007, The Journal of cell biology.

[19]  M. James,et al.  A NHERF binding site links the βPDGFR to the cytoskeleton and regulates cell spreading and migration , 2004, Journal of Cell Science.

[20]  Huiqi Pan,et al.  Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. , 2003, International journal of oncology.

[21]  S. Hirohashi,et al.  EBP50, a β‐catenin–associating protein, enhances Wnt signaling and is over‐expressed in hepatocellular carcinoma , 2003, Hepatology.